MGI Tech Co

MGI Tech Co EBITDA Margin

The EBITDA Margin of MGI Tech Co (688114.SS) as of Oct 22, 2026 is -5.89 %. In the previous year, EBITDA Margin was -1.48 % — a change of 296.76% (lower).

EBITDA Margin

-5.89 %

YoY

296.76%

Last updated:

EBITDA Margin of MGI Tech Co is 2025 -5.89 % . EBITDA Margin of MGI Tech Co was 2024 -1.48 % . It decreases by 296.76% lower compared to the previous year.

The MGI Tech Co EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2019
-2.28 CNY
Jan 1, 2020
16.05 CNY
Jan 1, 2021
23.71 CNY
Jan 1, 2022
11.18 CNY
Jan 1, 2023
-7.83 CNY
Jan 1, 2024
-1.48 CNY
Jan 1, 2025
-5.89 CNY
The MGI Tech Co EBITDA Margin history
YEAREBITDA MarginYoY
-5.89 %+296.76%
-1.48 %-81.03%
-7.83 %-169.97%
11.18 %-52.84%
23.71 %+47.74%
16.05 %-803.25%
-2.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

MGI Tech Co Stock analysis

What does MGI Tech Co do? MGI Tech Co., Ltd. generates revenue through the sale of DNA sequencing instruments, reagents, and related products for life science research, agriculture, precision medicine, and healthcare. The company's gene sequencer business offers desktop and large sequencers, creating a multi-model product range for diverse user needs. Laboratory automation products include automated sample processing systems, pipelines, and reagent consumables, targeting laboratories requiring efficient workflows. New business segments feature cytomic solutions, remote ultrasound robots, and bioinformation Technology (BIT) products, expanding into emerging applications. The primary customers are research institutions, agricultural companies, healthcare providers, and precision medicine facilities. These segments purchase the company's instruments, reagents, and automation systems to support their operations in genomics, diagnostics, and laboratory management. The gene sequencer and laboratory automation businesses form the core revenue streams, while new business products represent growth opportunities in innovative fields. MGI Tech's product portfolio spans multiple applications, with the gene sequencer business focusing on scalable sequencing solutions and laboratory automation addressing workflow efficiency. The new business segment introduces advanced technologies like remote ultrasound robots, targeting specialized healthcare environments. All products are sold directly to end-users in the specified sectors without mentioning third-party distributors or partners. MGI Tech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MGI Tech Co stock

EBITDA Margin of MGI Tech Co is -5.89 % in 2025.

EBITDA Margin of MGI Tech Co changed from -1.48 % to -5.89 %, representing a 296.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin MGI Tech Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's MGI Tech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — MGI Tech Co

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — MGI Tech Co